Research Paper Volume 16, Issue 5 pp 4811—4831
FHND004 inhibits malignant proliferation of multiple myeloma by targeting PDZ-binding kinase in MAPK pathway
Figure 2. FHND004 and FHND008 decrease the proliferation of MM cells through the MAPK pathway. (A) The volcano plot of gene expression in ARP1 WT and H929 WT with or without the treatment of FHND004 and FHND008, the red dots indicating significantly upregulated genes and green dots indicating significantly downregulated genes, and blue dots indicating those genes with no significant differential expressions. (B, C) KEGG pathway analysis of the RNA-seq data indicated that FHND004 and FHND008 were associated with the MAPK signaling pathway. (D, E) WB analysis of ERK1/2 and p-ERK1/2 expression in ARP1 WT, H929 WT with or without treatment of FHND004 (4 μM) (D) and FHND008 (4 μM) (E).